Atrial fibrillation management during septal myectomy for hypertrophic cardiomyopathy: A systematic review

Michael Seco1,2,3, Jonathan Cl Lau1,2, Caroline Medi1,4

  • 1Sydney Medical School, 7799University of Sydney, Australia.

Insights

Adding atrial fibrillation ablation during septal myectomy for hypertrophic cardiomyopathy appears safe and may reduce long-term recurrence. Further randomized trials are needed to confirm these findings for atrial fibrillation management.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Electrophysiology

Background:

  • Atrial fibrillation is prevalent in hypertrophic cardiomyopathy patients, significantly increasing mortality and morbidity.
  • Concomitant atrial fibrillation surgery during septal myectomy may improve outcomes in these patients.

Purpose of the Study:

  • To systematically review the outcomes of combined septal myectomy and atrial fibrillation surgery.
  • To assess the safety and efficacy of concomitant atrial fibrillation ablation in hypertrophic cardiomyopathy patients undergoing septal myectomy.

Main Methods:

  • Systematic review adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
  • Inclusion of all observational studies reporting outcomes of combined septal myectomy and atrial fibrillation surgery.

Main Results:

  • 10 observational studies including 644 patients were analyzed.
  • Cox-Maze IV was the most common ablation technique. Early outcomes showed variable rates of mortality, atrial tachyarrhythmia recurrence, cerebrovascular events, and pacemaker insertion.
  • Long-term freedom from atrial tachyarrhythmias ranged from 74-96% at 1 year and 52-100% at 5 years. Predictors of recurrence included left atrial diameter >45mm and persistent/longstanding atrial fibrillation.

Conclusions:

  • Concomitant atrial fibrillation ablation during septal myectomy adds minimal risk and likely reduces long-term atrial fibrillation recurrence.
  • Randomized studies are warranted to compare septal myectomy with and without concurrent atrial fibrillation ablation.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
69
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
66
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
96
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
50
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
165
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
59